The debate surrounding the use of medical cannabis has been a long and contentious one, with opinions varying across the globe.
However, recent research is shedding new light on the potential benefits of cannabinoid-based medicinal products (CBMPs), offering a glimmer of hope for patients suffering from chronic health conditions.
The breakthrough UK study, Project T21, researched the real-world effectiveness of medical cannabis, presenting compelling evidence that may tip the scales in favour of this ever popular alternative treatment option.
In an effort to assess the impact of medical cannabis on symptoms and quality of life, the study closely monitored patients using cannabis-based medicines for a range of conditions, including anxiety, chronic pain, and PTSD.
Notably, after just three months of treatment, patients reported significant improvements in their overall well-being and condition-specific symptoms. This promising outcome paves the way for further exploration into the potential therapeutic benefits of medical cannabis.
Incredible results across the board
In simple terms, this study looked at how medical cannabis affects the symptoms and quality of life for people who use it in the UK.
They collected information from patients who were using cannabis-based medicines for various conditions like anxiety, chronic pain, and PTSD.
The study found that people experienced improvements in their symptoms and overall well-being after using medical cannabis for three months.
While this study has some limitations, it does suggest that medical cannabis could be helpful for people with certain health conditions, and more research is needed to understand which patients can benefit most from it.
The results of Project T21, a study investigating the use of cannabinoid-based medicinal products (CBMPs) in a large cohort of individuals receiving treatment through private healthcare in the UK, indicate significant improvements in general health, quality of life, and condition-specific symptoms across a range of chronic health conditions.
These results provide compelling real-world evidence for the effectiveness of CBMPs in ameliorating symptoms and improving quality of life, as well as reducing the use of other prescribed medications.
A 50% reduction in Opioid use
The Project T21 study yielded a remarkable finding concerning the use of opioids for chronic pain management.
As participants incorporated medical cannabis into their treatment regimen, the study observed a significant 50% reduction in prescribed opioids among chronic pain patients.
This outcome suggests that cannabinoid-based medicinal products may offer an effective alternative to traditional opioid-based pain relief methods, which have been associated with addiction, overdose, and other serious side effects.
The potential for medical cannabis to reduce reliance on opioids could have profound implications for public health, as it may help address the ongoing opioid crisis and provide patients with a safer and more sustainable pain management solution.
Little adverse reactions in participants
In the Project T21 study, researchers observed that adverse events associated with the use of medical cannabis were quite rare, making it a relatively safe treatment option.
Out of the participants, only about 3% reported experiencing any side effects from the use of cannabinoid-based medicinal products. Importantly, these side effects were generally mild or moderate in severity, causing minimal disruption to the patients’ daily lives.
This low rate of adverse events highlights the potential safety of medical cannabis, dispelling some of the concerns that have previously hindered its widespread acceptance and usage.
The findings suggest that concerns about the potential adverse effects of cannabis may have been overly pessimistic.
The results of this study may help bridge the gap between the widespread support for legalising medicinal cannabis and the lack of randomized controlled trial (RCT) evidence for the efficacy of these medications.
Full details of the study are here:
https://journals.sagepub.com/doi/full/10.1177/20503245231167373
Related: Cannabis and Psychosis: A Groundbreaking Study Shatters UK Propaganda
